Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Apple Turns 50: From Garage Startup to AI Crossroads 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
JERSEY CITY, N.J., Jan. 31, 2017 -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will participate in the following upcoming investor conferences:
- Canaccord Genuity Rare Disease Conference at the InterContinental New York Barclay Hotel in New York City on Tuesday, February 7, 2017.
- RBC Capital Markets Global Healthcare Conference at the Lotte New York Palace Hotel in New York City on Wednesday, February 22, 2017. The Company will present at 3:35 p.m. ET.
A live webcast of the RBC presentation will be available on the Investors section of the Company's website: www.scynexis.com. A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.
About SCYNEXIS
SCYNEXIS is a pharmaceutical company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and IV drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. For more information, visit www.scynexis.com.
CONTACT: Media Relations Blair McCarthy Atkinson MacDougall Biomedical Communications Tel: 781.235.3060 [email protected] Investor Relations Susan Kim Argot Partners Tel: 212-203-4433 [email protected]
